[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f19sbVrJVdO6LH6Xz_pjsGYl9a3v9BTCrsMKmMH8K4-A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":80,"rows":87},"American University of Beirut Medical Center",[4],155,false,25,17,103972,13,90,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Obesity",7,{"name":18,"count":19},"Anesthesia",5,{"name":21,"count":22},"Weight Loss",4,{"name":24,"count":22},"Infertility",{"name":26,"count":22},"Sterility",{"name":28,"count":29},"Intubation; Difficult or Failed",3,{"name":31,"count":29},"Childhood Obesity",{"name":33,"count":29},"Amyotrophic Lateral Sclerosis",[35,40,45,50,55,60,65,70,75],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT07168135","Effect of Discontinuing Propofol After Cecal Intubation on Patient's Psychomotor Recovery Following Colonoscopy","2025-11","propofol",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT02706704","Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","2025-12","Adalimumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT04153032","Comparative Evaluation of MEBO Ointment and Topical Diltiazem Ointment in the Treatment of Acute Anal Fissure","2026-01-01","Diltiazem",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05913180","Vitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological Surgeries","2026-08-15","Ascorbic Acid 1000 MG",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT04194424","A Multidisciplinary Weight Loss Program at AUB-MC","2026-09-15","Metformin Hcl 850Mg Tab",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07561411","Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy","2028-05-01","Paravertebral block",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06686381","Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo\u002FImmunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W","2028-08","Chemotherapy + Immunotherapy Induction",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06903585","Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy","2029-04","Naproxen",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07387848","Glofitamab as a Bridge to and\u002For Consolidation Post Autologous Stem Cell Transplant in Patients With Relapsed B Cell Lymphomas","2031-12-15","Glofitamab",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,132,156,174,197,215,238,256,277,300,339,364,382,402,438,463,489,507,531,558,576,603,621,647,672,690,712,741,759,777,802,828,846,864,890,915,939,963,989,1007,1044,1071,1089,1115,1133,1159,1185,1203,1227,1255,1281,1299,1326,1344,1362,1388,1406,1432,1456,1480,1506,1530,1552,1578,1596,1622,1645,1670,1688,1715,1739,1768,1799,1824,1842,1860,1893,1911,1929,1947,1965,1983,2001,2019,2044,2067,2091,2120,2138,2163,2181,2199,2225,2243,2261,2286],{"intervention":54,"totalTrials":29,"cells":89},{"EARLY_PHASE1":90,"PHASE1":113,"PHASE2":115,"PHASE3":126,"PHASE4":128,"NA":130},{"trials":91,"activeCount":100},[92,105],{"nctId":93,"briefTitle":94,"status":95,"phases":96,"primaryCompletion":97,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},"NCT04261036","Vitamin C for the Prevention of UTI in Women Who Undergo Elective Gynecological Surgeries","WITHDRAWN",[81],"2021-07-01","2021-10-01","2019-07-20",0,[102],"Catheter-Associated Urinary Tract Infection, Ascorbic Acid",[104],"Ascorbic Acid 1000 mg",{"nctId":106,"briefTitle":107,"status":95,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":100,"conditions":111,"interventions":112},"NCT03800667","Vitamin C for the Prevention of UTI in Women Who Undergo Elective GYN Surgeries",[81],"2019-07-12","2018-08-08",[102],[54],{"trials":114,"activeCount":100},[],{"trials":116,"activeCount":125,"soonestReadout":53},[117],{"nctId":51,"briefTitle":52,"status":118,"phases":119,"primaryCompletion":53,"completion":53,"start":120,"enrollment":121,"conditions":122,"interventions":124},"RECRUITING",[83],"2023-09-19",180,[123],"Catheter-Associated Urinary Tract Infection",[54],1,{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"intervention":74,"totalTrials":125,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":150,"PHASE4":152,"NA":154},{"trials":135,"activeCount":100},[],{"trials":137,"activeCount":100},[],{"trials":139,"activeCount":125,"soonestReadout":73},[140],{"nctId":71,"briefTitle":72,"status":141,"phases":142,"primaryCompletion":73,"completion":73,"start":143,"enrollment":144,"conditions":145,"interventions":148},"NOT_YET_RECRUITING",[83],"2025-04",385,[146,147],"Bone Pain Flare","Bone Metastasis",[74,149],"Esomeprazole 20mg once daily",{"trials":151,"activeCount":100},[],{"trials":153,"activeCount":100},[],{"trials":155,"activeCount":100},[],{"intervention":149,"totalTrials":125,"cells":157},{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":159,"activeCount":100},[],{"trials":161,"activeCount":100},[],{"trials":163,"activeCount":125,"soonestReadout":73},[164],{"nctId":71,"briefTitle":72,"status":141,"phases":165,"primaryCompletion":73,"completion":73,"start":143,"enrollment":144,"conditions":166,"interventions":167},[83],[146,147],[74,149],{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":100},[],{"intervention":49,"totalTrials":125,"cells":175},{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":177,"activeCount":100},[],{"trials":179,"activeCount":100},[],{"trials":181,"activeCount":125,"soonestReadout":48},[182],{"nctId":46,"briefTitle":47,"status":118,"phases":183,"primaryCompletion":48,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},[83],"2026-01-30","2019-12-01",183,[188],"Anal Fissure",[49,190],"Mebo",{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"trials":196,"activeCount":100},[],{"intervention":190,"totalTrials":125,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":125,"soonestReadout":48},[205],{"nctId":46,"briefTitle":47,"status":118,"phases":206,"primaryCompletion":48,"completion":184,"start":185,"enrollment":186,"conditions":207,"interventions":208},[83],[188],[49,190],{"trials":210,"activeCount":100},[],{"trials":212,"activeCount":100},[],{"trials":214,"activeCount":100},[],{"intervention":69,"totalTrials":125,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":125,"soonestReadout":68},[223],{"nctId":66,"briefTitle":67,"status":141,"phases":224,"primaryCompletion":68,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},[83],"2028-08-15","2025-04-15",80,[229],"Muscle-invasive Bladder Cancer",[69,231],"Immunotherapy Maintenance",{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"trials":237,"activeCount":100},[],{"intervention":231,"totalTrials":125,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":250,"PHASE4":252,"NA":254},{"trials":241,"activeCount":100},[],{"trials":243,"activeCount":100},[],{"trials":245,"activeCount":125,"soonestReadout":68},[246],{"nctId":66,"briefTitle":67,"status":141,"phases":247,"primaryCompletion":68,"completion":225,"start":226,"enrollment":227,"conditions":248,"interventions":249},[83],[229],[69,231],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"trials":255,"activeCount":100},[],{"intervention":79,"totalTrials":125,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":271,"PHASE4":273,"NA":275},{"trials":259,"activeCount":100},[],{"trials":261,"activeCount":100},[],{"trials":263,"activeCount":125,"soonestReadout":78},[264],{"nctId":76,"briefTitle":77,"status":141,"phases":265,"primaryCompletion":78,"completion":78,"start":266,"enrollment":267,"conditions":268,"interventions":270},[83],"2026-04-15",40,[269],"Diffuse Large B Cell Lymphoma Refractory",[79],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"trials":276,"activeCount":100},[],{"intervention":44,"totalTrials":125,"cells":278},{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":100},[],{"trials":284,"activeCount":125,"soonestReadout":43},[285],{"nctId":41,"briefTitle":42,"status":118,"phases":286,"primaryCompletion":43,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":293},[83],"2026-02","2016-02",32,[291,292],"Uveitis","Non-Infectious Uveitis",[44],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":100},[],{"intervention":39,"totalTrials":301,"cells":302},2,{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":304,"activeCount":100},[],{"trials":306,"activeCount":100},[],{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"trials":312,"activeCount":100},[],{"trials":314,"activeCount":125,"soonestReadout":38},[315,326],{"nctId":36,"briefTitle":37,"status":316,"phases":317,"primaryCompletion":38,"completion":43,"start":318,"enrollment":319,"conditions":320,"interventions":325},"ACTIVE_NOT_RECRUITING",[86],"2025-05-19",100,[321,322,323,324],"Procedural Sedation","Colonoscopy","Cecal Intubation Success Rate","Propofol Adverse Reaction",[39],{"nctId":327,"briefTitle":328,"status":329,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT03553082","Airway Complications After LMA in Children","COMPLETED",[86],"2021-05-28","2018-05-18",135,[335],"Anesthesia Recovery",[337,338],"Sevoflurane","Propofol",{"intervention":64,"totalTrials":125,"cells":340},{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":351},{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":125,"soonestReadout":63},[353],{"nctId":61,"briefTitle":62,"status":118,"phases":354,"primaryCompletion":63,"completion":63,"start":355,"enrollment":356,"conditions":357,"interventions":362},[86],"2026-05-19",132,[358,359,360,361],"Mastectomy; Lymphedema","Chronic Pain","Regional Anesthesia Morbidity","Opioid Use",[64,363],"Erector Spinae block",{"intervention":363,"totalTrials":125,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":100},[],{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":125,"soonestReadout":63},[378],{"nctId":61,"briefTitle":62,"status":118,"phases":379,"primaryCompletion":63,"completion":63,"start":355,"enrollment":356,"conditions":380,"interventions":381},[86],[358,359,360,361],[64,363],{"intervention":59,"totalTrials":125,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":385,"activeCount":100},[],{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":100},[],{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":125,"soonestReadout":58},[396],{"nctId":56,"briefTitle":57,"status":316,"phases":397,"primaryCompletion":58,"completion":58,"start":398,"enrollment":399,"conditions":400,"interventions":401},[86],"2023-08-15",20,[15,21],[59],{"intervention":403,"totalTrials":301,"cells":404},"Myo-inositol",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":425,"NA":436},{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":100},[],{"trials":412,"activeCount":100},[413],{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":424},"NCT04273256","Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial","UNKNOWN",[83,84],"2022-02","2023-02","2020-02-11",226,[423],"Poor Ovarian Response",[403],{"trials":426,"activeCount":100},[427],{"nctId":428,"briefTitle":429,"status":416,"phases":430,"primaryCompletion":431,"completion":432,"start":433,"enrollment":319,"conditions":434,"interventions":435},"NCT03177122","Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology",[85],"2023-12-01","2023-12-31","2017-03-01",[26,24],[403],{"trials":437,"activeCount":100},[],{"intervention":439,"totalTrials":125,"cells":440},"Varinecline",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":461},{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":100},[],{"trials":446,"activeCount":100},[],{"trials":448,"activeCount":100},[],{"trials":450,"activeCount":100},[451],{"nctId":452,"briefTitle":453,"status":329,"phases":454,"primaryCompletion":455,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":460},"NCT02575183","Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation",[85],"2021-03-01","2016-08-31",152,[459],"Nicotine Dependence",[439],{"trials":462,"activeCount":100},[],{"intervention":464,"totalTrials":125,"cells":465},"4 mg of Ondansetron IV",{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":487},{"trials":467,"activeCount":100},[],{"trials":469,"activeCount":100},[],{"trials":471,"activeCount":100},[],{"trials":473,"activeCount":100},[],{"trials":475,"activeCount":100},[476],{"nctId":477,"briefTitle":478,"status":329,"phases":479,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":485},"NCT02143531","Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting",[85],"2012-08","2008-09",120,[484],"Postoperative Nausea and Vomiting",[464,486],"1mg of Haloperidol IV",{"trials":488,"activeCount":100},[],{"intervention":486,"totalTrials":125,"cells":490},{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":505},{"trials":492,"activeCount":100},[],{"trials":494,"activeCount":100},[],{"trials":496,"activeCount":100},[],{"trials":498,"activeCount":100},[],{"trials":500,"activeCount":100},[501],{"nctId":477,"briefTitle":478,"status":329,"phases":502,"primaryCompletion":480,"completion":480,"start":481,"enrollment":482,"conditions":503,"interventions":504},[85],[484],[464,486],{"trials":506,"activeCount":100},[],{"intervention":508,"totalTrials":125,"cells":509},"Ascorbic Acid",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":529},{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":100},[520],{"nctId":521,"briefTitle":522,"status":329,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":227,"conditions":526,"interventions":528},"NCT01322061","Vitamin C Efficacy in Reducing Post Operative Pain",[85],"2011-07","2010-11",[527],"Gallbladder Inflammation",[508],{"trials":530,"activeCount":100},[],{"intervention":532,"totalTrials":125,"cells":533},"Captafer®",{"EARLY_PHASE1":534,"PHASE1":536,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":556},{"trials":535,"activeCount":100},[],{"trials":537,"activeCount":100},[],{"trials":539,"activeCount":100},[],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":100},[544],{"nctId":545,"briefTitle":546,"status":416,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":399,"conditions":551,"interventions":554},"NCT02774057","Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD",[85],"2017-07","2017-08","2016-03",[552,553],"Iron Deficiency Anemia","Inflammatory Bowel Disease",[532,555],"Iron Sulfate",{"trials":557,"activeCount":100},[],{"intervention":555,"totalTrials":125,"cells":559},{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":574},{"trials":561,"activeCount":100},[],{"trials":563,"activeCount":100},[],{"trials":565,"activeCount":100},[],{"trials":567,"activeCount":100},[],{"trials":569,"activeCount":100},[570],{"nctId":545,"briefTitle":546,"status":416,"phases":571,"primaryCompletion":548,"completion":549,"start":550,"enrollment":399,"conditions":572,"interventions":573},[85],[552,553],[532,555],{"trials":575,"activeCount":100},[],{"intervention":577,"totalTrials":125,"cells":578},"mild stimulation protocol: oral Clomiphene Citrate",{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":601},{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":100},[589],{"nctId":590,"briefTitle":591,"status":416,"phases":592,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":597,"interventions":599},"NCT04157725","Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization",[85],"2025-01-01","2025-07-01","2023-06-01",154,[598,24],"PCO - Polycystic Ovaries",[577,600],"Conventional Stimulation Protocol: will receive FSH\u002FHMG",{"trials":602,"activeCount":100},[],{"intervention":600,"totalTrials":125,"cells":604},{"EARLY_PHASE1":605,"PHASE1":607,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":619},{"trials":606,"activeCount":100},[],{"trials":608,"activeCount":100},[],{"trials":610,"activeCount":100},[],{"trials":612,"activeCount":100},[],{"trials":614,"activeCount":100},[615],{"nctId":590,"briefTitle":591,"status":416,"phases":616,"primaryCompletion":593,"completion":594,"start":595,"enrollment":596,"conditions":617,"interventions":618},[85],[598,24],[577,600],{"trials":620,"activeCount":100},[],{"intervention":622,"totalTrials":125,"cells":623},"Natalis",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":645},{"trials":625,"activeCount":100},[],{"trials":627,"activeCount":100},[],{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":100},[],{"trials":633,"activeCount":100},[634],{"nctId":635,"briefTitle":636,"status":329,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT03518684","Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma",[85],"2019-06-28","2019-06-30","2018-04-03",160,[643],"Labor Stage, Second",[622],{"trials":646,"activeCount":100},[],{"intervention":648,"totalTrials":125,"cells":649},"Phenylephrine",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":670},{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":100},[],{"trials":655,"activeCount":100},[],{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[660],{"nctId":661,"briefTitle":662,"status":329,"phases":663,"primaryCompletion":664,"completion":664,"start":665,"enrollment":227,"conditions":666,"interventions":668},"NCT01378325","Variable Rate Phenylephrine Infusion for Prevention of Spinal-induced Hypotension for Cesarean Delivery",[85],"2013-01","2012-07",[667],"Anesthetic Complication Spinal",[648,669],"saline",{"trials":671,"activeCount":100},[],{"intervention":669,"totalTrials":125,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":688},{"trials":675,"activeCount":100},[],{"trials":677,"activeCount":100},[],{"trials":679,"activeCount":100},[],{"trials":681,"activeCount":100},[],{"trials":683,"activeCount":100},[684],{"nctId":661,"briefTitle":662,"status":329,"phases":685,"primaryCompletion":664,"completion":664,"start":665,"enrollment":227,"conditions":686,"interventions":687},[85],[667],[648,669],{"trials":689,"activeCount":100},[],{"intervention":691,"totalTrials":125,"cells":692},"Triptorelin",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":710},{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"trials":698,"activeCount":100},[],{"trials":700,"activeCount":100},[],{"trials":702,"activeCount":100},[703],{"nctId":704,"briefTitle":705,"status":329,"phases":706,"primaryCompletion":97,"completion":98,"start":433,"enrollment":707,"conditions":708,"interventions":709},"NCT03169166","The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies",[85],277,[26,24],[691],{"trials":711,"activeCount":100},[],{"intervention":713,"totalTrials":125,"cells":714},"dexmedetomidine 0.25 µg\u002Fkg IV",{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":739},{"trials":716,"activeCount":100},[],{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":100},[725],{"nctId":726,"briefTitle":727,"status":329,"phases":728,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":732,"interventions":736},"NCT02141412","Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia",[85],"2015-09","2009-09",216,[335,733,734,735],"Anesthesia Emergence","Shivering","Postoperative Recovery",[713,737,738],"dexmedetomidine 0.5 µg\u002Fkg IV","dexmedetomidine 1 µg\u002Fkg IV",{"trials":740,"activeCount":100},[],{"intervention":737,"totalTrials":125,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":749,"PHASE4":751,"NA":757},{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":100},[],{"trials":750,"activeCount":100},[],{"trials":752,"activeCount":100},[753],{"nctId":726,"briefTitle":727,"status":329,"phases":754,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":755,"interventions":756},[85],[335,733,734,735],[713,737,738],{"trials":758,"activeCount":100},[],{"intervention":738,"totalTrials":125,"cells":760},{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":775},{"trials":762,"activeCount":100},[],{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[771],{"nctId":726,"briefTitle":727,"status":329,"phases":772,"primaryCompletion":729,"completion":729,"start":730,"enrollment":731,"conditions":773,"interventions":774},[85],[335,733,734,735],[713,737,738],{"trials":776,"activeCount":100},[],{"intervention":778,"totalTrials":125,"cells":779},"Pylera based reduced regimen",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":800},{"trials":781,"activeCount":100},[],{"trials":783,"activeCount":100},[],{"trials":785,"activeCount":100},[],{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":100},[790],{"nctId":791,"briefTitle":792,"status":95,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":100,"conditions":797,"interventions":799},"NCT02045251","An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection",[85],"2016-07","2016-09","2013-06",[798],"Treatment of H. Pylori Infection",[778],{"trials":801,"activeCount":100},[],{"intervention":803,"totalTrials":125,"cells":804},"Sugammadex",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":826},{"trials":806,"activeCount":100},[],{"trials":808,"activeCount":100},[],{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[815],{"nctId":816,"briefTitle":817,"status":329,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":823},"NCT02375217","\"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy\"",[85],"2015-10","2014-10",56,[335],[803,803,824,825],"Neostigmine","glycopyrrolate",{"trials":827,"activeCount":100},[],{"intervention":824,"totalTrials":125,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":844},{"trials":831,"activeCount":100},[],{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[840],{"nctId":816,"briefTitle":817,"status":329,"phases":841,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":842,"interventions":843},[85],[335],[803,803,824,825],{"trials":845,"activeCount":100},[],{"intervention":825,"totalTrials":125,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":862},{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[858],{"nctId":816,"briefTitle":817,"status":329,"phases":859,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":860,"interventions":861},[85],[335],[803,803,824,825],{"trials":863,"activeCount":100},[],{"intervention":865,"totalTrials":125,"cells":866},"Dexlansoprazole 60 MG",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":888},{"trials":868,"activeCount":100},[],{"trials":870,"activeCount":100},[],{"trials":872,"activeCount":100},[],{"trials":874,"activeCount":100},[],{"trials":876,"activeCount":100},[877],{"nctId":878,"briefTitle":879,"status":329,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":883,"conditions":884,"interventions":887},"NCT03079050","An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan",[85],"2017-07-30","2017-02-27",33,[885,886],"GERD","Proton Pump Inhibitor",[865],{"trials":889,"activeCount":100},[],{"intervention":891,"totalTrials":125,"cells":892},"Rabeprazole, metronidazole, Clarithromycin, Amoxicillin",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":913},{"trials":894,"activeCount":100},[],{"trials":896,"activeCount":100},[],{"trials":898,"activeCount":100},[],{"trials":900,"activeCount":100},[],{"trials":902,"activeCount":100},[903],{"nctId":904,"briefTitle":905,"status":329,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT01219764","A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection",[85],"2013-03","2010-10",200,[911],"Helicobacter Infections",[891],{"trials":914,"activeCount":100},[],{"intervention":916,"totalTrials":125,"cells":917},"Progesterone",{"EARLY_PHASE1":918,"PHASE1":920,"PHASE2":922,"PHASE3":924,"PHASE4":926,"NA":937},{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[928],{"nctId":929,"briefTitle":930,"status":329,"phases":931,"primaryCompletion":932,"completion":98,"start":933,"enrollment":934,"conditions":935,"interventions":936},"NCT03619707","Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles",[85],"2021-08-01","2018-08-01",157,[26,24],[916],{"trials":938,"activeCount":100},[],{"intervention":940,"totalTrials":125,"cells":941},"Bemiparin sodium",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":961},{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"trials":949,"activeCount":100},[],{"trials":951,"activeCount":100},[952],{"nctId":953,"briefTitle":954,"status":329,"phases":955,"primaryCompletion":956,"completion":956,"start":957,"enrollment":958,"conditions":959,"interventions":960},"NCT02607319","Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure",[85],"2022-07","2015-11",165,[26],[940],{"trials":962,"activeCount":100},[],{"intervention":964,"totalTrials":125,"cells":965},"Sodium Picosulfate\u002FMagnesium Citrate Laxative",{"EARLY_PHASE1":966,"PHASE1":968,"PHASE2":970,"PHASE3":972,"PHASE4":974,"NA":987},{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"trials":975,"activeCount":100},[976],{"nctId":977,"briefTitle":978,"status":416,"phases":979,"primaryCompletion":980,"completion":980,"start":981,"enrollment":982,"conditions":983,"interventions":985},"NCT03581149","Tolerability and Efficacy of Sodium Picosulfate\u002FMagnesium Citrate Versus PEG\u002FAscorbic Acid in Ulcerative Colitis Patients",[85],"2020-07-26","2018-03-26",68,[984],"Ulcerative Colitis",[964,986],"2L polyethylene glycol\u002Fascorbic acid",{"trials":988,"activeCount":100},[],{"intervention":986,"totalTrials":125,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":999,"NA":1005},{"trials":992,"activeCount":100},[],{"trials":994,"activeCount":100},[],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[1001],{"nctId":977,"briefTitle":978,"status":416,"phases":1002,"primaryCompletion":980,"completion":980,"start":981,"enrollment":982,"conditions":1003,"interventions":1004},[85],[984],[964,986],{"trials":1006,"activeCount":100},[],{"intervention":1008,"totalTrials":301,"cells":1009},"Misoprostol",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1016,"PHASE4":1040,"NA":1042},{"trials":1011,"activeCount":100},[],{"trials":1013,"activeCount":100},[],{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":100},[1018,1030],{"nctId":1019,"briefTitle":1020,"status":1021,"phases":1022,"primaryCompletion":1023,"completion":1024,"start":1025,"enrollment":1026,"conditions":1027,"interventions":1029},"NCT00141895","A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death","TERMINATED",[84],"2008-10","2008-11","2004-09",73,[1028],"Labor Induction",[1008,1008],{"nctId":1031,"briefTitle":1032,"status":329,"phases":1033,"completion":1034,"start":1035,"enrollment":1036,"conditions":1037,"interventions":1039},"NCT00140114","Sublingual Versus Vaginal Misoprostol for Labor Induction at Term",[84],"2006-09","2004-01",170,[1038],"Induction of Labor",[1008],{"trials":1041,"activeCount":100},[],{"trials":1043,"activeCount":100},[],{"intervention":1045,"totalTrials":125,"cells":1046},"Dual trigger",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1067,"NA":1069},{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":100},[],{"trials":1054,"activeCount":100},[1055],{"nctId":1056,"briefTitle":1057,"status":329,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT04224818","Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders",[84],"2019-08-20","2019-08-30","2018-07-11",140,[1064],"Poor Ovarian Reserve",[1045,1066],"hCG",{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[],{"intervention":1066,"totalTrials":125,"cells":1072},{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1085,"NA":1087},{"trials":1074,"activeCount":100},[],{"trials":1076,"activeCount":100},[],{"trials":1078,"activeCount":100},[],{"trials":1080,"activeCount":100},[1081],{"nctId":1056,"briefTitle":1057,"status":329,"phases":1082,"primaryCompletion":1059,"completion":1060,"start":1061,"enrollment":1062,"conditions":1083,"interventions":1084},[84],[1064],[1045,1066],{"trials":1086,"activeCount":100},[],{"trials":1088,"activeCount":100},[],{"intervention":1090,"totalTrials":125,"cells":1091},"Microfragmented Adipose Tissue Transplant",{"EARLY_PHASE1":1092,"PHASE1":1094,"PHASE2":1096,"PHASE3":1098,"PHASE4":1111,"NA":1113},{"trials":1093,"activeCount":100},[],{"trials":1095,"activeCount":100},[],{"trials":1097,"activeCount":100},[],{"trials":1099,"activeCount":100},[1100],{"nctId":1101,"briefTitle":1102,"status":416,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1109},"NCT04230902","Effects of α MAT Versus Steroid Injection in Knee Osteoarthritis (STα MAT-knee Study)",[84],"2021-03-31","2019-03-04",48,[1108],"Knee Osteoarthritis",[1090,1110],"Corticosteroid",{"trials":1112,"activeCount":100},[],{"trials":1114,"activeCount":100},[],{"intervention":1110,"totalTrials":125,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1123,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":100},[],{"trials":1120,"activeCount":100},[],{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":100},[1125],{"nctId":1101,"briefTitle":1102,"status":416,"phases":1126,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1127,"interventions":1128},[84],[1108],[1090,1110],{"trials":1130,"activeCount":100},[],{"trials":1132,"activeCount":100},[],{"intervention":1134,"totalTrials":125,"cells":1135},"Yasmin",{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1155,"NA":1157},{"trials":1137,"activeCount":100},[],{"trials":1139,"activeCount":100},[],{"trials":1141,"activeCount":100},[],{"trials":1143,"activeCount":100},[1144],{"nctId":1145,"briefTitle":1146,"status":416,"phases":1147,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":319,"conditions":1151,"interventions":1153},"NCT04256200","Efficacy of Dienogest Versus Oral Contraceptive Pills on Pain Associated With Endometriosis",[83,84],"2021-11","2021-12","2017-02-07",[1152],"Endometriosis",[1154,1134],"Dienogest 2 MG Oral",{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"intervention":1160,"totalTrials":125,"cells":1161},"Furosemide",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1181,"NA":1183},{"trials":1163,"activeCount":100},[],{"trials":1165,"activeCount":100},[],{"trials":1167,"activeCount":100},[],{"trials":1169,"activeCount":100},[1170],{"nctId":1171,"briefTitle":1172,"status":416,"phases":1173,"primaryCompletion":1174,"completion":1174,"start":1175,"enrollment":909,"conditions":1176,"interventions":1179},"NCT05769738","The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation",[84],"2024-12","2023-03",[1177,1178],"Chronic Obstructive Pulmonary Disease Exacerbation","COPD Exacerbation",[1160,1180],"Normal saline",{"trials":1182,"activeCount":100},[],{"trials":1184,"activeCount":100},[],{"intervention":1180,"totalTrials":125,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1199,"NA":1201},{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[1195],{"nctId":1171,"briefTitle":1172,"status":416,"phases":1196,"primaryCompletion":1174,"completion":1174,"start":1175,"enrollment":909,"conditions":1197,"interventions":1198},[84],[1177,1178],[1160,1180],{"trials":1200,"activeCount":100},[],{"trials":1202,"activeCount":100},[],{"intervention":1204,"totalTrials":125,"cells":1205},"Ursodeoxycholic Acid",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1223,"NA":1225},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[1214],{"nctId":1215,"briefTitle":1216,"status":416,"phases":1217,"primaryCompletion":1218,"completion":1219,"start":550,"enrollment":319,"conditions":1220,"interventions":1222},"NCT02721862","Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy",[84],"2018-09","2019-03",[1221],"Cholelithiasis",[1204],{"trials":1224,"activeCount":100},[],{"trials":1226,"activeCount":100},[],{"intervention":1228,"totalTrials":125,"cells":1229},"Morphine",{"EARLY_PHASE1":1230,"PHASE1":1232,"PHASE2":1234,"PHASE3":1236,"PHASE4":1251,"NA":1253},{"trials":1231,"activeCount":100},[],{"trials":1233,"activeCount":100},[],{"trials":1235,"activeCount":100},[],{"trials":1237,"activeCount":100},[1238],{"nctId":1239,"briefTitle":1240,"status":329,"phases":1241,"primaryCompletion":957,"completion":1242,"start":1243,"enrollment":1244,"conditions":1245,"interventions":1249},"NCT02213159","Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery",[83,84],"2015-12","2014-07",60,[15,1246,1247,1248],"Sleep Apnea","Diabetes","Hypertension",[1250,1228],"Dexmedetomidine",{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":100},[],{"intervention":1256,"totalTrials":125,"cells":1257},"Sucrosomial Iron",{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1277,"NA":1279},{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":100},[1266],{"nctId":1267,"briefTitle":1268,"status":416,"phases":1269,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1275},"NCT05225545","Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis",[84],"2024-05-04","2019-11-04",30,[1274,984],"Anemia, Iron Deficiency",[1256,1276],"Oral Iron",{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"intervention":1276,"totalTrials":125,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[],{"trials":1288,"activeCount":100},[],{"trials":1290,"activeCount":100},[1291],{"nctId":1267,"briefTitle":1268,"status":416,"phases":1292,"primaryCompletion":1270,"completion":1270,"start":1271,"enrollment":1272,"conditions":1293,"interventions":1294},[84],[1274,984],[1256,1276],{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":100},[],{"intervention":1300,"totalTrials":125,"cells":1301},"Sucrose",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1322,"NA":1324},{"trials":1303,"activeCount":100},[],{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[1310],{"nctId":1311,"briefTitle":1312,"status":329,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1242,"enrollment":1316,"conditions":1317,"interventions":1319},"NCT02990364","Combination Analgesia for Neonatal Circumcision",[84],"2016-12","2017-01",70,[1318],"Analgesia",[1300,1320,1321],"Lidocaine","EMLA Topical Product",{"trials":1323,"activeCount":100},[],{"trials":1325,"activeCount":100},[],{"intervention":1320,"totalTrials":125,"cells":1327},{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1334,"PHASE4":1340,"NA":1342},{"trials":1329,"activeCount":100},[],{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":100},[1336],{"nctId":1311,"briefTitle":1312,"status":329,"phases":1337,"primaryCompletion":1314,"completion":1315,"start":1242,"enrollment":1316,"conditions":1338,"interventions":1339},[84],[1318],[1300,1320,1321],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":100},[],{"intervention":1321,"totalTrials":125,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1358,"NA":1360},{"trials":1347,"activeCount":100},[],{"trials":1349,"activeCount":100},[],{"trials":1351,"activeCount":100},[],{"trials":1353,"activeCount":100},[1354],{"nctId":1311,"briefTitle":1312,"status":329,"phases":1355,"primaryCompletion":1314,"completion":1315,"start":1242,"enrollment":1316,"conditions":1356,"interventions":1357},[84],[1318],[1300,1320,1321],{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[],{"intervention":1363,"totalTrials":125,"cells":1364},"nefopam, ketoprofen, paracetamol",{"EARLY_PHASE1":1365,"PHASE1":1367,"PHASE2":1369,"PHASE3":1371,"PHASE4":1384,"NA":1386},{"trials":1366,"activeCount":100},[],{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[1373],{"nctId":1374,"briefTitle":1375,"status":329,"phases":1376,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":12,"conditions":1379,"interventions":1382},"NCT04622813","Nonopioid Analgesics and Cholecystectomy",[84],"2022-10-19","2021-04-08",[1380,1381,361],"Cholecystectomy","Pain, Postoperative",[1363,1383],"saline infusion, ketoprofen, paracetamol",{"trials":1385,"activeCount":100},[],{"trials":1387,"activeCount":100},[],{"intervention":1383,"totalTrials":125,"cells":1389},{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1402,"NA":1404},{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[1398],{"nctId":1374,"briefTitle":1375,"status":329,"phases":1399,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":12,"conditions":1400,"interventions":1401},[84],[1380,1381,361],[1363,1383],{"trials":1403,"activeCount":100},[],{"trials":1405,"activeCount":100},[],{"intervention":1407,"totalTrials":125,"cells":1408},"Nifedipine",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1413,"PHASE3":1415,"PHASE4":1428,"NA":1430},{"trials":1410,"activeCount":100},[],{"trials":1412,"activeCount":100},[],{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[1417],{"nctId":1418,"briefTitle":1419,"status":1021,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":1423,"enrollment":1424,"conditions":1425,"interventions":1427},"NCT00137501","Two Dose Regimens of Nifedipine for the Management of Preterm Labor",[84],"2009-01","2009-06","2003-05",102,[1426],"Labor, Premature",[1407],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":100},[],{"intervention":1433,"totalTrials":125,"cells":1434},"patient will be reversed with sugammadex 4mg\u002Fkg IV",{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1452,"NA":1454},{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[1443],{"nctId":1444,"briefTitle":1445,"status":329,"phases":1446,"primaryCompletion":1447,"completion":1447,"start":332,"enrollment":482,"conditions":1448,"interventions":1451},"NCT01937247","Redesigned Process in the Operating Room",[83,84],"2020-10-30",[1449,1450],"Non-operative Time","General Surgery, Above 18 Years of Age",[1433],{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":100},[],{"intervention":1457,"totalTrials":125,"cells":1458},"Mosapride Citrate",{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1476,"NA":1478},{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"trials":1466,"activeCount":100},[1467],{"nctId":1468,"briefTitle":1469,"status":1021,"phases":1470,"primaryCompletion":1471,"completion":1471,"start":481,"enrollment":1472,"conditions":1473,"interventions":1475},"NCT00742872","Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome",[84],"2010-06",41,[1474],"Constipation-Predominant Irritable Bowel Syndrome",[1457],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"intervention":1481,"totalTrials":125,"cells":1482},"Apraclonidine Hcl 0.5% Oph Soln",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1484,"activeCount":100},[],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":100},[1489],{"nctId":1490,"briefTitle":1491,"status":329,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1499},"NCT05045248","Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis",[83],"2021-04-15","2020-06-01",10,[1497,1498],"Myasthenia Gravis","Ocular Myasthenia Gravis",[1481],{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[],{"intervention":1507,"totalTrials":125,"cells":1508},"Biotin",{"EARLY_PHASE1":1509,"PHASE1":1511,"PHASE2":1513,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[1515],{"nctId":1516,"briefTitle":1517,"status":329,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":1520,"enrollment":1521,"conditions":1522,"interventions":1523},"NCT03427086","Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis",[83],"2021-05-10","2018-01-29",12,[33],[1507],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"intervention":1531,"totalTrials":125,"cells":1532},"Fycompa",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1546,"PHASE4":1548,"NA":1550},{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[1539],{"nctId":1540,"briefTitle":1541,"status":1021,"phases":1542,"primaryCompletion":1494,"completion":97,"start":185,"enrollment":1543,"conditions":1544,"interventions":1545},"NCT03377309","Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients",[83],6,[33],[1531],{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"intervention":1553,"totalTrials":125,"cells":1554},"17-alpha Hydroxyprogesterone Caproate",{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1572,"PHASE4":1574,"NA":1576},{"trials":1556,"activeCount":100},[],{"trials":1558,"activeCount":100},[],{"trials":1560,"activeCount":100},[1561],{"nctId":1562,"briefTitle":1563,"status":329,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1570},"NCT00141908","Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate",[83],"2012-12","2006-10",290,[1569],"Preterm Delivery",[1553,1571],"Castor oil",{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[],{"intervention":1571,"totalTrials":125,"cells":1579},{"EARLY_PHASE1":1580,"PHASE1":1582,"PHASE2":1584,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1581,"activeCount":100},[],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[1586],{"nctId":1562,"briefTitle":1563,"status":329,"phases":1587,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":1588,"interventions":1589},[83],[1569],[1553,1571],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"intervention":1597,"totalTrials":125,"cells":1598},"Betamethasone",{"EARLY_PHASE1":1599,"PHASE1":1601,"PHASE2":1603,"PHASE3":1616,"PHASE4":1618,"NA":1620},{"trials":1600,"activeCount":100},[],{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[1605],{"nctId":1606,"briefTitle":1607,"status":416,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1615},"NCT01206946","Efficacy of Antenatal Steroids in Reducing Respiratory Morbidities in Late Preterm Infants",[83],"2013-09","2010-09",700,[1613,1614],"Respiratory Distress Syndrome, Newborn","Transient Tachypnea of the Newborn",[1597],{"trials":1617,"activeCount":100},[],{"trials":1619,"activeCount":100},[],{"trials":1621,"activeCount":100},[],{"intervention":1623,"totalTrials":125,"cells":1624},"BMS-936558",{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[1631],{"nctId":1632,"briefTitle":1633,"status":1021,"phases":1634,"primaryCompletion":1635,"completion":1635,"start":1493,"enrollment":125,"conditions":1636,"interventions":1638},"NCT04648319","A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma",[83],"2022-01-17",[1637],"Cholangiocarcinoma",[1623],{"trials":1640,"activeCount":100},[],{"trials":1642,"activeCount":100},[],{"trials":1644,"activeCount":100},[],{"intervention":1646,"totalTrials":125,"cells":1647},"Oxaliplatin",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1664,"PHASE4":1666,"NA":1668},{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[1654],{"nctId":1655,"briefTitle":1656,"status":1021,"phases":1657,"completion":1658,"start":1659,"enrollment":267,"conditions":1660,"interventions":1662},"NCT00403988","Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma",[83],"2007-12","2004-06",[1661],"Breast Neoplasms",[1646,1663],"vinorelbine",{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"intervention":1663,"totalTrials":125,"cells":1671},{"EARLY_PHASE1":1672,"PHASE1":1674,"PHASE2":1676,"PHASE3":1682,"PHASE4":1684,"NA":1686},{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[1678],{"nctId":1655,"briefTitle":1656,"status":1021,"phases":1679,"completion":1658,"start":1659,"enrollment":267,"conditions":1680,"interventions":1681},[83],[1661],[1646,1663],{"trials":1683,"activeCount":100},[],{"trials":1685,"activeCount":100},[],{"trials":1687,"activeCount":100},[],{"intervention":1689,"totalTrials":125,"cells":1690},"Control group",{"EARLY_PHASE1":1691,"PHASE1":1693,"PHASE2":1707,"PHASE3":1709,"PHASE4":1711,"NA":1713},{"trials":1692,"activeCount":100},[],{"trials":1694,"activeCount":100},[1695],{"nctId":1696,"briefTitle":1697,"status":329,"phases":1698,"primaryCompletion":1699,"completion":1700,"start":1701,"enrollment":1702,"conditions":1703,"interventions":1706},"NCT03399331","Honey or Olive Oil for Treating Oral Mucositis in Children and Adults With Leukemia Receiving Intensive Chemotherapy",[82],"2021-12-01","2024-06-01","2017-07-10",45,[1704,1705],"Oral Mucositis","Leukemia",[1689],{"trials":1708,"activeCount":100},[],{"trials":1710,"activeCount":100},[],{"trials":1712,"activeCount":100},[],{"trials":1714,"activeCount":100},[],{"intervention":1716,"totalTrials":125,"cells":1717},"Letrozole",{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[1722],{"nctId":1723,"briefTitle":1724,"status":95,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":100,"conditions":1728,"interventions":1730},"NCT00945360","Aromatase Inhibitors for Treatment of Uterine Leiomyomas",[82],"2011-05","2011-03",[1729],"Symptomatic or Large Uterine Fibroids",[1716],{"trials":1732,"activeCount":100},[],{"trials":1734,"activeCount":100},[],{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"intervention":1740,"totalTrials":301,"cells":1741},"Dienogest 2 MG",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"trials":1749,"activeCount":100},[1750],{"nctId":1145,"briefTitle":1146,"status":416,"phases":1751,"primaryCompletion":1148,"completion":1149,"start":1150,"enrollment":319,"conditions":1752,"interventions":1753},[83,84],[1152],[1154,1134],{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[1758],{"nctId":1759,"briefTitle":1760,"status":416,"phases":1761,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1766},"NCT03142035","Dienogest Versus GnRH-a Pre-treatment in Women With Endometriosis Undergoing IVF",[86],"2023-02-22","2017-10-22",189,[1152],[1740,1767],"gonapeptyl",{"intervention":1250,"totalTrials":301,"cells":1769},{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1774,"PHASE3":1776,"PHASE4":1782,"NA":1784},{"trials":1771,"activeCount":100},[],{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":100},[],{"trials":1777,"activeCount":100},[1778],{"nctId":1239,"briefTitle":1240,"status":329,"phases":1779,"primaryCompletion":957,"completion":1242,"start":1243,"enrollment":1244,"conditions":1780,"interventions":1781},[83,84],[15,1246,1247,1248],[1250,1228],{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[1786],{"nctId":1787,"briefTitle":1788,"status":329,"phases":1789,"primaryCompletion":1790,"completion":1790,"start":480,"enrollment":1791,"conditions":1792,"interventions":1798},"NCT05342870","A Sequential Allocation Study to Determine the ED50 of Dexmetedomidine as an Adjuvant to Lidocaine Intravenous Regional Anesthesia",[86],"2013-08",23,[1793,1250,1794,1795,1796,1797],"Bier Block","Tourniquet Pain","Carpal Tunnel","Tendon Release","Tendn Transfer",[1250],{"intervention":1800,"totalTrials":125,"cells":1801},"platelet-rich plasma group",{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1803,"activeCount":100},[],{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":100},[1814],{"nctId":1815,"briefTitle":1816,"status":1021,"phases":1817,"primaryCompletion":1315,"completion":1818,"start":729,"enrollment":1819,"conditions":1820,"interventions":1822},"NCT02669303","Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome",[86],"2017-01-01",19,[1821],"Shoulder Impingement Syndrome",[1800,1823],"Methylprednisolone group",{"intervention":1823,"totalTrials":125,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"trials":1831,"activeCount":100},[],{"trials":1833,"activeCount":100},[],{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[1838],{"nctId":1815,"briefTitle":1816,"status":1021,"phases":1839,"primaryCompletion":1315,"completion":1818,"start":729,"enrollment":1819,"conditions":1840,"interventions":1841},[86],[1821],[1800,1823],{"intervention":1767,"totalTrials":125,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"trials":1849,"activeCount":100},[],{"trials":1851,"activeCount":100},[],{"trials":1853,"activeCount":100},[],{"trials":1855,"activeCount":100},[1856],{"nctId":1759,"briefTitle":1760,"status":416,"phases":1857,"primaryCompletion":1762,"completion":1762,"start":1763,"enrollment":1764,"conditions":1858,"interventions":1859},[86],[1152],[1740,1767],{"intervention":1861,"totalTrials":125,"cells":1862},"e-liquid 1",{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1864,"activeCount":100},[],{"trials":1866,"activeCount":100},[],{"trials":1868,"activeCount":100},[],{"trials":1870,"activeCount":100},[],{"trials":1872,"activeCount":100},[],{"trials":1874,"activeCount":100},[1875],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1882,"interventions":1885},"NCT05430334","Assess the Influence of Nicotine Flux and Nicotine Form on Subjective Effects Related to Dependency",[86],"2025-07-11","2022-07-13",130,[1883,459,1884],"Nicotine Vaping","Nicotine Addiction",[1861,1886,1887,1888,1889,1890,1891,1892],"e-liquid 2","e-liquid 3","e-liquid 4","e-liquid 5","e-liquid 6","e-liquid 7 and e-liquid 8","e-liquid 9 and e-liquid 10",{"intervention":1886,"totalTrials":125,"cells":1894},{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1896,"activeCount":100},[],{"trials":1898,"activeCount":100},[],{"trials":1900,"activeCount":100},[],{"trials":1902,"activeCount":100},[],{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[1907],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1908,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1909,"interventions":1910},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1887,"totalTrials":125,"cells":1912},{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[],{"trials":1922,"activeCount":100},[],{"trials":1924,"activeCount":100},[1925],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1926,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1927,"interventions":1928},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1888,"totalTrials":125,"cells":1930},{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1935,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"trials":1936,"activeCount":100},[],{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[1943],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1944,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1945,"interventions":1946},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1889,"totalTrials":125,"cells":1948},{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"trials":1954,"activeCount":100},[],{"trials":1956,"activeCount":100},[],{"trials":1958,"activeCount":100},[],{"trials":1960,"activeCount":100},[1961],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1962,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1963,"interventions":1964},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1890,"totalTrials":125,"cells":1966},{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1968,"activeCount":100},[],{"trials":1970,"activeCount":100},[],{"trials":1972,"activeCount":100},[],{"trials":1974,"activeCount":100},[],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[1979],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1980,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1981,"interventions":1982},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1891,"totalTrials":125,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1995},{"trials":1986,"activeCount":100},[],{"trials":1988,"activeCount":100},[],{"trials":1990,"activeCount":100},[],{"trials":1992,"activeCount":100},[],{"trials":1994,"activeCount":100},[],{"trials":1996,"activeCount":100},[1997],{"nctId":1876,"briefTitle":1877,"status":329,"phases":1998,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":1999,"interventions":2000},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":1892,"totalTrials":125,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2009,"PHASE4":2011,"NA":2013},{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[],{"trials":2014,"activeCount":100},[2015],{"nctId":1876,"briefTitle":1877,"status":329,"phases":2016,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":1881,"conditions":2017,"interventions":2018},[86],[1883,459,1884],[1861,1886,1887,1888,1889,1890,1891,1892],{"intervention":2020,"totalTrials":125,"cells":2021},"Cocoa butter application",{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2028,"PHASE4":2030,"NA":2032},{"trials":2023,"activeCount":100},[],{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[2034],{"nctId":2035,"briefTitle":2036,"status":329,"phases":2037,"completion":2038,"start":2039,"enrollment":909,"conditions":2040,"interventions":2043},"NCT00114660","Cocoa Butter for Prevention of Stretch Marks",[86],"2006-07","2004-11",[2041,2042],"Striae Gravidarum","Pregnancy",[2020],{"intervention":2045,"totalTrials":125,"cells":2046},"Oxytocin",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2048,"activeCount":100},[],{"trials":2050,"activeCount":100},[],{"trials":2052,"activeCount":100},[],{"trials":2054,"activeCount":100},[],{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[2059],{"nctId":2060,"briefTitle":2061,"status":329,"phases":2062,"primaryCompletion":2063,"completion":2063,"start":665,"enrollment":909,"conditions":2064,"interventions":2066},"NCT00891150","Oxytocin to Decrease Blood Loss During Cesarean Section",[86],"2013-02",[2065],"Complications; Cesarean Section",[2045],{"intervention":2068,"totalTrials":125,"cells":2069},"Nilotinib",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2071,"activeCount":100},[],{"trials":2073,"activeCount":100},[],{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":100},[],{"trials":2081,"activeCount":100},[2082],{"nctId":2083,"briefTitle":2084,"status":329,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":2087,"enrollment":11,"conditions":2088,"interventions":2090},"NCT01316250","Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia",[86],"2025-07","2010-08",[2089],"Chronic Myelogenous Leukemia",[2068],{"intervention":2092,"totalTrials":125,"cells":2093},"Lark",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2095,"activeCount":100},[],{"trials":2097,"activeCount":100},[],{"trials":2099,"activeCount":100},[],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"trials":2105,"activeCount":100},[2106],{"nctId":2107,"briefTitle":2108,"status":329,"phases":2109,"primaryCompletion":2110,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2118},"NCT03321331","A Self-directed Mobile Intervention to Promote Weight Control Among Employees of a Lebanese University",[86],"2018-07-30","2018-03-05",123,[2114,2115,2116,2117],"Body Weight Changes","Overweight and Obesity","Sedentary Lifestyle","Health Behavior",[2092,2119],"MyFitnessPal",{"intervention":2119,"totalTrials":125,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2132},{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"trials":2131,"activeCount":100},[],{"trials":2133,"activeCount":100},[2134],{"nctId":2107,"briefTitle":2108,"status":329,"phases":2135,"primaryCompletion":2110,"completion":2110,"start":2111,"enrollment":2112,"conditions":2136,"interventions":2137},[86],[2114,2115,2116,2117],[2092,2119],{"intervention":2139,"totalTrials":125,"cells":2140},"sevoflurane via LMA",{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2147,"PHASE4":2149,"NA":2151},{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[],{"trials":2148,"activeCount":100},[],{"trials":2150,"activeCount":100},[],{"trials":2152,"activeCount":100},[2153],{"nctId":2154,"briefTitle":2155,"status":329,"phases":2156,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":1244,"conditions":2159,"interventions":2161},"NCT06656455","Sevoflurane and Laryngeal Mask Airway Versus Propofol Infusion and Facemask for EUA in Children",[86],"2024-07-08","2017-05-23",[18,2160],"Children, Only",[2139,2162],"Propofol with oxygen via simple mask",{"intervention":2162,"totalTrials":125,"cells":2164},{"EARLY_PHASE1":2165,"PHASE1":2167,"PHASE2":2169,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[],{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[2177],{"nctId":2154,"briefTitle":2155,"status":329,"phases":2178,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":1244,"conditions":2179,"interventions":2180},[86],[18,2160],[2139,2162],{"intervention":337,"totalTrials":125,"cells":2182},{"EARLY_PHASE1":2183,"PHASE1":2185,"PHASE2":2187,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2184,"activeCount":100},[],{"trials":2186,"activeCount":100},[],{"trials":2188,"activeCount":100},[],{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[],{"trials":2194,"activeCount":100},[2195],{"nctId":327,"briefTitle":328,"status":329,"phases":2196,"primaryCompletion":331,"completion":331,"start":332,"enrollment":333,"conditions":2197,"interventions":2198},[86],[335],[337,338],{"intervention":2200,"totalTrials":125,"cells":2201},"Combined spinal epidural anesthesia technique with intrathecal morphine",{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":100},[],{"trials":2213,"activeCount":100},[2214],{"nctId":2215,"briefTitle":2216,"status":329,"phases":2217,"primaryCompletion":2218,"completion":2218,"start":907,"enrollment":2219,"conditions":2220,"interventions":2222},"NCT02135120","The Efficacy of Peripheral Nerve Blocks With Intrathecal Morphine in Improving Analgesia After Unilateral Total Knee Arthroplasty",[86],"2017-02",42,[18,2221],"Total Knee Arthroplasty",[2200,2223,2224],"A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block","A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block",{"intervention":2223,"totalTrials":125,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2228,"activeCount":100},[],{"trials":2230,"activeCount":100},[],{"trials":2232,"activeCount":100},[],{"trials":2234,"activeCount":100},[],{"trials":2236,"activeCount":100},[],{"trials":2238,"activeCount":100},[2239],{"nctId":2215,"briefTitle":2216,"status":329,"phases":2240,"primaryCompletion":2218,"completion":2218,"start":907,"enrollment":2219,"conditions":2241,"interventions":2242},[86],[18,2221],[2200,2223,2224],{"intervention":2224,"totalTrials":125,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":100},[],{"trials":2252,"activeCount":100},[],{"trials":2254,"activeCount":100},[],{"trials":2256,"activeCount":100},[2257],{"nctId":2215,"briefTitle":2216,"status":329,"phases":2258,"primaryCompletion":2218,"completion":2218,"start":907,"enrollment":2219,"conditions":2259,"interventions":2260},[86],[18,2221],[2200,2223,2224],{"intervention":2262,"totalTrials":125,"cells":2263},"Fentanyl",{"EARLY_PHASE1":2264,"PHASE1":2266,"PHASE2":2268,"PHASE3":2270,"PHASE4":2272,"NA":2274},{"trials":2265,"activeCount":100},[],{"trials":2267,"activeCount":100},[],{"trials":2269,"activeCount":100},[],{"trials":2271,"activeCount":100},[],{"trials":2273,"activeCount":100},[],{"trials":2275,"activeCount":100},[2276],{"nctId":2277,"briefTitle":2278,"status":329,"phases":2279,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":2283,"interventions":2285},"NCT02099877","μ-opioid Receptor Polymorphism and Opioid Analgesia",[],"2017-06","2013-10",250,[2284],"Pharmacogenetic and Duration of Labor Fentanyl Analgesia",[2262],{"intervention":2287,"totalTrials":125,"cells":2288},"Rabeprazole or Esomeprazole or Lanzoprazole",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2293,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2290,"activeCount":100},[],{"trials":2292,"activeCount":100},[],{"trials":2294,"activeCount":100},[],{"trials":2296,"activeCount":100},[],{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[2301],{"nctId":2302,"briefTitle":2303,"status":329,"phases":2304,"primaryCompletion":2305,"completion":2305,"start":2306,"enrollment":2307,"conditions":2308,"interventions":2310},"NCT01139645","The Effect of Proton Pump Inhibitors on Calcium and Bone Metabolism",[86],"2010-07","2009-10",58,[2309],"Calcium Metabolism Disorders",[2287]]